HIMS vs. DOCS: Which Digital Health Platform Is a Better Investment?

A comparative analysis of digital health platforms Hims & Hers (HIMS) and Doximity (DOCS) positions HIMS as a more compelling investment, despite both companies trading above sector average valuations. HIMS, a consumer-focused platform, is diversifying offerings, expanding globally with an $870 million convertible note raise, and investing heavily in AI, projecting a 122.2% EPS improvement for 2025. In contrast, DOCS, a physician-centric network with high professional engagement and AI integration, forecasts a 6.3% EPS improvement for fiscal 2026 but trades at a significantly higher price-to-sales multiple (20.9x vs. HIMS's 4.6x), indicating HIMS offers a more stable and financially sound opportunity with lower execution risk.

Analysis

Hims & Hers Health (HIMS) and Doximity (DOCS) represent two distinct strategies in the digital health sector, with HIMS operating a direct-to-consumer model and DOCS a physician-centric network. HIMS has demonstrated extraordinary stock performance, rallying 208.8% over the past year, driven by diversification into high-growth markets like weight loss, international expansion funded by an $870 million convertible note offering, and a projected 2025 EPS improvement of 122.2%. In contrast, DOCS, despite its dominant network encompassing over 80% of U.S. physicians and strong engagement with its AI tools like Scribe, shows a more modest fiscal 2026 EPS growth forecast of 6.3%. The valuation disparity is stark: HIMS trades at a 4.6x forward price-to-sales (P/S) ratio, whereas DOCS trades at a significantly higher 20.9x. This suggests investors are pricing in substantial future growth for DOCS that is not yet reflected in earnings projections. A notable conflict exists between the stocks' momentum and analyst expectations; the average price target for HIMS implies an 11.3% decline, while the target for DOCS suggests a 7.5% upside, creating a complex risk-reward profile for both.

Key Decisions for Investors

• Investors bullish on HIMS should focus on its aggressive expansion into new verticals like weight loss and its triple-digit projected EPS growth, which may justify its valuation despite analyst price targets suggesting a near-term pullback after its 208.8% annual gain.
• Caution is warranted for Doximity, as its elevated 20.9x forward P/S multiple appears stretched when compared to its modest 6.3% projected EPS growth, indicating high execution risk and potential for valuation compression.
• Consider a relative value approach by favoring HIMS over DOCS, based on the significant divergence in valuation multiples against forward earnings growth projections, which presents HIMS as a more compelling growth-at-a-reasonable-price candidate within the digital health space.
• Monitor HIMS's execution on its international expansion and AI integration, as its ability to deploy the recently raised $870 million in capital effectively will be critical to sustaining its growth trajectory and validating its current share price.